Vaccination is considered by the World Health Organization (WHO) as the most cost-effective 48 strategy for controlling infectious diseases that prevent 2.5 million of deaths every year (WHO, 49 2005) . Despite of the great success of vaccination, many infectious diseases are still leading 50 killers, mainly due to their insufficient vaccination coverage (WHO, 2009; Drain et al. 2003) . A 51 number of factors have been responsible of the logistical challenges to attain high immunization 52 coverage: required doses on immunization schedules, parenteral immunization, high vaccine 53 reactogenicity, few studies targeting antigens-combinations on vaccine formulations, vaccine 54 cold chain, vaccination policy, countries weak immunization programmes, high cost and not 55 affordability for poor countries, among others (Jiang et al. 2005) . Only live-attenuated vaccines 56 like BCG and Polio induce good protection with a single dose. In contrast, to obtain good 57 immune response with a single dose by non-living antigen vaccines multiple doses are generally 58 needed, in order to provide sufficient stimulation of the immune system and to achieve long-59 lasting immune responses. The number of doses is especially relevant in developing countries, 60
where the population has not easy access to medical services and vaccination campaigns are 61 very difficult, much more when several doses are required, which cause loses the entire 62 immunization schedule (Aguado and Lambert 1992) . So, the development of new immunization 63 strategies that allow complete immunization scheme with a single visit without further contact 64 could be as important as to develop single-dose vaccines. 65
Traditionally, adjuvants have been used to enhance the magnitude of the adaptive response to a 66 vaccine. However, a second role has become increasingly important: guiding the type of adaptive 67 response to produce the most effective forms of immunity for each specific pathogen (Th1, Th2, 68 induce cross-presentation, and cytotoxic T-lymphocyte activity (CTL) (Rodriguez et al. 2005 and 88 Rodriguez et al. 2006) . AFCo1 can be used mainly as mucosal adjuvant because it is a stable 89 particle with higher mucosal absorption (Del Campo et al. 2009 ) and acid resistant properties. 90
Mucosal surface is exposed to a diverse and very large number of microorganisms and also is the 91 site of infection of diverse pathogens (e.g., influenza virus, Vibrio cholerae, type I reovirus, and 92 rhinovirus) (Plotkin, 2005) . The initial mucosal infection can only be prevented by mucosal 93 immune responses (pathogen-specific secretory IgA (SIgA) or local cytotoxic T lymphocytes 94 (CTL)) (Brandtzaeg, 2009) . Mucosal immunization elicits systemic specific immune response 95 and stimulates the specific mucosal immune response, leading by the production of SIgA 96 D r a f t antibody. Also, it is less invasive route; does not require trained personnel; and significantly 97 decreases the risk of parenteral transmitted diseases (Mann et al. 2009; Neutra and Kozlowski, 98 2006) . In our experience mucosal route requires larger antigen amount and number of doses than 99 parenteral route to obtain similar systemic responses (Del Campo et al. 2009 ). In addition, 100 parenteral immunization has been shown induction of memory IgA in different vaccines, such as 101 influenza, Pseudomonas aeruginosa, and inactivated polio vaccines (attributed to previous 102 natural mucosal infection by these organisms) (Kaul and Ogra, 1998) . Indeed, a combined 103 mucosal and parenteral poliovirus immunization strategy has been shown to effectively induce 104 high neutralizing antibodies in serum as well as mucosal immune responses in humans. 105
Strategies which combine together parenteral and mucosal immunizations (Treanor et al. 1992; 106 Morrison et al. 1998) , such as mucosal prime-parenteral booster (Lee et al. 1999; Faden et al. 107 1990) or parenteral prime-mucosal booster (29Keren et al. 1988) have generated stronger 108 immune responses than either of these routes by themselves. 109
In the light of the ambitious goal of vaccines providing maximum protection at both parenteral 110 and mucosal levels with minimum number of doses; we set out to develop a novel vaccination 111 strategy, called Single Time Vaccination Strategy (SinTimVaS) (Perez et al. 2008; Gonzalez et 112 al. 2009 at Finlay Institute, Havana, Cuba (9). AFPL1 was absorbed onto aluminium hydroxide (Alum). 135
AFCo1 was obtained in our laboratory starting from PL, through a process of exchange of 136 sodium deoxycholate (DOC) and the divalent cation calcium as described by Pérez et al (8) . The 137 formation of cochleate structure was visualized by the appearance of a white suspension in the 138 preparation and by light microscopy analysis. BSA protein was supplied from Sigma, Aldrich. 139
Immunization schedules 140
Groups of 5 female mice were immunized simultaneously by i.m injection of AFPL1 (12.5 µg) 141 or by mucosal (i.n, s.l, or o.r) administration of AFCo1 (50 µg). Also, groups of mice were 142 immunized 2 times (days 0 and 14) i.m with AFPL1 (12.5 µg), and 3 times (days 0, 7 and 14) 143 i.n (12.5 µL/nostril) with AFCo1 (50 µg). With heterologous antigens, mice were immunized 144 using the same scheme described above. Each dose contained BSA (10 µg per mouse per dose) 145 plus AFPL1 (12.5 µg) or TT (2Lf (limit 
Samples collection 153
Samples were collected as follows. saliva and faeces were collected on the 7 day after the last 154 dose, serum and vaginal washes on the 21st days after the last dose (12-30). Saliva samples were 155 taken following salivation stimulation with 50µL intraperitoneal injection of pilocarpine (0.5% 156 (v/v) Quimefa, Cuba). Saliva was inactivated for 15 min at 56ºC, centrifuged at 10000 g for 10 157 min and stored until it was used. Three to 6 pieces freshly voided faeces were collected into 1.5 158 mL pre-weighed micro-centrifuge tubes and phosphate buffered saline (PBS, pH 7.2) was added 159 with protease inhibitors (1 mM phenylmethyl sulfonylfluoride in ethanol, 5 µg/mL of aprotinin 160 and 1 µL/mL of leupeptin, antipain and pepstatin (all from Sigma) in a ratio of 20 µL per mg of 161 faeces. Solid matter was resuspended by extensive vortex and centrifuged at 10000 g for 10 min 162 and the supernatants were stored. Vaginal cavities were rinsed 3 times with 50 µL of PBS, 163 centrifuged and immediately stored. Blood was collected by puncturing the retro-orbital plexus 164 using microhematocrit capillary tubes. The serum was removed by centrifugation at 5000g for 10 165 min. All samples were stored at -20°C until ELISA's assays were conducted. (Fig. 4A) . Also, the response at the systemic level in all SinTimVaS 241 combinations were significantly superior (p<0.05) to 3 doses of each mucosal route. Figure 4B  242 show that we detected a slight increase in anti-BSA IgA response in mice immunized with 243 i.n/i.m and o.r/i.m combinations when compared with each only-mucosal scheme, respectively. 244 
